Find Darolutamide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Weekly News Recap #Phispers

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Odm-201, 1297538-32-9, Bay-1841788, Nubeqa, Bay1841788, Darolutamide [usan]
Molecular Formula
C19H19ClN6O2
Molecular Weight
398.8  g/mol
InChI Key
BLIJXOOIHRSQRB-PXYINDEMSA-N
FDA UNII
X05U0N2RCO

Darolutamide
Darolutamide is a formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.
1 2D Structure

Darolutamide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
2.1.2 InChI
InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1
2.1.3 InChI Key
BLIJXOOIHRSQRB-PXYINDEMSA-N
2.1.4 Canonical SMILES
CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O
2.1.5 Isomeric SMILES
C[C@@H](CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O
2.2 Other Identifiers
2.2.1 UNII
X05U0N2RCO
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Nubeqa

2. Odm-201

3. Orm-16497

4. Orm-16555

2.3.2 Depositor-Supplied Synonyms

1. Odm-201

2. 1297538-32-9

3. Bay-1841788

4. Nubeqa

5. Bay1841788

6. Darolutamide [usan]

7. N-((s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide

8. Bay 1841788

9. X05u0n2rco

10. Odm-201;bay-1841788

11. 1h-pyrazole-3-carboxamide, N-((1s)-2-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)-1-methylethyl)-5-(1-hydroxyethyl)-

12. N-((s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)-propan-2-yl)-3-(1-hydroxyethyl)-1h-pyrazole-5-carboxamide

13. Odm201

14. 1h-pyrazole-3-carboxamide, N-[(1s)-2-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-

15. Nebeqa (tn)

16. Darolutamide [mi]

17. Odm-201(darolutamide)

18. Darolutamide [inn]

19. Darolutamide [jan]

20. Unii-x05u0n2rco

21. Darolutamide (odm-201)

22. Darolutamide [who-dd]

23. Darolutamide (jan/usan/inn)

24. Schembl1814935

25. Chembl4297185

26. Schembl13733117

27. Gtpl10439

28. Ex-a759

29. Bdbm309979

30. Darolutamide [orange Book]

31. Dtxsid101027953

32. Example 56 [us9657003]

33. N-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide

34. Bdbm50556205

35. Mfcd29472270

36. Nsc825331

37. Akos030526387

38. Ccg-268640

39. Cs-5174

40. Db12941

41. Nsc-825331

42. Ncgc00484078-01

43. Ac-32628

44. As-75032

45. Bay-1841788)

46. Hy-16985

47. S7559

48. J3.501.129c

49. D11045

50. Us9657003, 56

51. A888821

52. J-690121

53. Q25091391

54. 1-[(2s)-2-butanyl]-n-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-1h-indole-4-car Boxamide

55. N-((2s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol- 1-yl)propan-2-yl)-5-((1rs)-1-hydroxyethyl)-1h-pyrazole- 3-carboxamide

56. N-((2s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)propan-2-yl)-5-((1rs)-1-hydroxyethyl)-1h-pyrazole-3-carboxamide

57. N-((s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol -1-yl)propan-2-yl)-3-(1-hydroxyethyl)-1h-pyrazole-5-carboxamide

58. N-((s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxy-ethyl)-1h-pyrazole-3-carboxamide

59. N-[(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide

2.4 Create Date
2012-11-30
3 Chemical and Physical Properties
Molecular Weight 398.8 g/mol
Molecular Formula C19H19ClN6O2
XLogP31.8
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Exact Mass398.1258016 g/mol
Monoisotopic Mass398.1258016 g/mol
Topological Polar Surface Area120 Ų
Heavy Atom Count28
Formal Charge0
Complexity598
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

This drug is indicated for the treatment of patients diagnosed with non-metastatic and castrate-resistant prostate cancer.


FDA Label


Nubeqa is indicated for the treatment of adult men with non metastatic castration resistant prostate cancer (nmCRPC) who are at risk of developing metastatic disease.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Darolutamide, through its downstream effects on cancer cell growth, treats castrate-resistant prostate cancer. It inhibits cancer cell growth and markedly lowers prostate specific antigen (PSA) levels through potent androgen receptor antagonism.


5.2 ATC Code

L02BB


L - Antineoplastic and immunomodulating agents

L02 - Endocrine therapy

L02B - Hormone antagonists and related agents

L02BB - Anti-androgens

L02BB06 - Darolutamide


5.3 Absorption, Distribution and Excretion

Absorption

Darolutamide is absorbed in the gastrointestinal tract. In the fasted state, peak concentrations are reached within 3-5 hours, and within 3-8 hours in the fed state. Median Tmax is between 3-6 hours.The average darolutamide steady-state peak plasma concentration after a 600 mg twice daily dose is approximately 4.79 mg/L. The Cmax is attained approximately 4 hours after administration of a single 600 mg oral dose. The AUC 0-12h is approximately 52.82 hg/mL. **Effects of food** The absolute bioavailability of darolutamide is approximately 30% after fasting and taking a single 300 mg dose. Steady-state concentrations are attained between 2 and 5 days after repeated administration with food. The bioavailability of darolutamide increases by 2.0 to 2.5 times when it is given with food.


Route of Elimination

In a pharmacokinetic study, a radiolabeled dose of darolutamide in an oral solution showed that 63.4% of darolutamide-related material was excreted in the urine (7% of which was unchanged drug) and 32.4% in the feces (with 30% unchanged drug).


Volume of Distribution

After intravenous administration, the apparent volume of distribution of darolutamide is about 119L.


Clearance

The clearance of darolutamide after an intravenous dose is 116 mL/min (39.7%).


5.4 Metabolism/Metabolites

Darolutamide is mainly metabolized by the CYP3A4 hepatic microsomal enzyme in addition to UGT1A9 and UGT1A1. The main active metabolite keto-darolutamide in found in the plasma at 2 times the concentration of darolutamide.


5.5 Biological Half-Life

The half-life of darolutamide and its active metabolite, keto-darolutamide is about 20 hours. A phase 1 study determined a terminal half life ranging between 10-15 hours.


5.6 Mechanism of Action

The actions of androgens on androgen receptors (AR) potentiate the growth and survival of prostate cancer cells. Darolutamide competitively inhibits androgens from binding to their receptors, inhibiting AR nuclear translocation, as well as AR-mediated transcription. The end result of these processes is a decrease in prostate cancer cell proliferation and tumor size. Its main metabolite, keto-darolutamide, shows similar pharmacological activity to the parent drug, darolutamide. Darolutamide has been found to bind more tightly to the AR receptor than [apalutamide] and [enzalutamide], which are other androgen receptor antagonists. Darolutamide can act as a progesterone receptor (PR) antagonist in the laboratory setting with approximately 1% activity when compared to its actions at the androgen receptor. The clinical relevance is not known at this time.


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"DAROLUTAMIDE","year":"2021","qtr":"Q1","strtotime":1611253800,"product":"DAROLUTAMIDE (TAX INVOICE NO:1905205233 DT:06.01.2021)(GROUP:A","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"LGM PHARMA","customerCountry":"UNITED STATES","quantity":"0.02","actualQuantity":"0.02","unit":"KGS","unitRateFc":"3509.8","totalValueFC":"71.1","currency":"USD","unitRateINR":259900,"date":"22-Jan-2021","totalValueINR":"5198","totalValueInUsd":"71.1","indian_port":"HYDERABAD AIR","hs_no":"29331990","bill_no":"8078039","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669228200,"product":"DAROLUTAMIDE AMORPHOUS (DLM2) WO","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"TO THE ORDER OF.","customerCountry":"BANGLADESH","quantity":"0.60","actualQuantity":"0.6","unit":"KGS","unitRateFc":"12000","totalValueFC":"7131.2","currency":"USD","unitRateINR":970000,"date":"24-Nov-2022","totalValueINR":"582000","totalValueInUsd":"7131.2","indian_port":"HYDERABAD AIR","hs_no":"29331999","bill_no":"5686019","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1721586600,"product":"DAROLUTAMIDE (CAS NO: 1297538-32-9) (AS PER INVOICE)","address":"802, BLOCK-A, ALPINE HEIGHTS","city":"HYDERABAD, A.P.","supplier":"HONG KONG AURISCO ","supplierCountry":"CHINA","foreign_port":"HANGCHOW (HANGZHOU)","customer":"ALFRED E TIEFENBACHER GMBH","customerCountry":"INDIA","quantity":"0.15","actualQuantity":"0.15","unit":"KGS","unitRateFc":"10000","totalValueFC":"1517.2","currency":"USD","unitRateINR":"845500","date":"22-Jul-2024","totalValueINR":"126825","totalValueInUsd":"1517.2","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"4645960","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HANGCHOW (HANGZHOU)","supplierAddress":"RM D 10\/F TOWER A BILLION CTR1 WANG KWONG RD KOWLOON BAY KLSDNF HK","customerAddress":"802, BLOCK-A, ALPINE HEIGHTS"}]
22-Jan-2021
22-Jul-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Darolutamide Manufacturers

A Darolutamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Darolutamide, including repackagers and relabelers. The FDA regulates Darolutamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Darolutamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Darolutamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Darolutamide Suppliers

A Darolutamide supplier is an individual or a company that provides Darolutamide active pharmaceutical ingredient (API) or Darolutamide finished formulations upon request. The Darolutamide suppliers may include Darolutamide API manufacturers, exporters, distributors and traders.

click here to find a list of Darolutamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Darolutamide USDMF

A Darolutamide DMF (Drug Master File) is a document detailing the whole manufacturing process of Darolutamide active pharmaceutical ingredient (API) in detail. Different forms of Darolutamide DMFs exist exist since differing nations have different regulations, such as Darolutamide USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Darolutamide DMF submitted to regulatory agencies in the US is known as a USDMF. Darolutamide USDMF includes data on Darolutamide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Darolutamide USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Darolutamide suppliers with USDMF on PharmaCompass.

Darolutamide KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Darolutamide Drug Master File in Korea (Darolutamide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Darolutamide. The MFDS reviews the Darolutamide KDMF as part of the drug registration process and uses the information provided in the Darolutamide KDMF to evaluate the safety and efficacy of the drug.

After submitting a Darolutamide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Darolutamide API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Darolutamide suppliers with KDMF on PharmaCompass.

Darolutamide WC

A Darolutamide written confirmation (Darolutamide WC) is an official document issued by a regulatory agency to a Darolutamide manufacturer, verifying that the manufacturing facility of a Darolutamide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Darolutamide APIs or Darolutamide finished pharmaceutical products to another nation, regulatory agencies frequently require a Darolutamide WC (written confirmation) as part of the regulatory process.

click here to find a list of Darolutamide suppliers with Written Confirmation (WC) on PharmaCompass.

Darolutamide NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Darolutamide as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Darolutamide API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Darolutamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Darolutamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Darolutamide NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Darolutamide suppliers with NDC on PharmaCompass.

Darolutamide GMP

Darolutamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Darolutamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Darolutamide GMP manufacturer or Darolutamide GMP API supplier for your needs.

Darolutamide CoA

A Darolutamide CoA (Certificate of Analysis) is a formal document that attests to Darolutamide's compliance with Darolutamide specifications and serves as a tool for batch-level quality control.

Darolutamide CoA mostly includes findings from lab analyses of a specific batch. For each Darolutamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Darolutamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Darolutamide EP), Darolutamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Darolutamide USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty